Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Reference: Osimertinib with Platinum-Pemetrexed for Advanced EGFR-Mutated NSCLC
The FLAURA2 trial found that osimertinib plus chemotherapy resulted in significantly longer overall survival compared to osimertinib alone in patients with EGFR-mutated advanced NS
New Indication: Pembrolizumab with Platinum-5FU for Advanced Penile Cancer
In patients with advanced penile squamous cell carcinoma, pembrolizumab combined with platinum-based chemotherapy showed an overall response rate of 39.4%, with manageable toxic ef
New Reference: Lenvatinib + Pembrolizumab for Melanoma
Lenvatinib plus pembrolizumab did not show additional clinical benefit over pembrolizumab alone in advanced melanoma. Although progression-free survival was initially improved, ove
New Reference: Nivolumab + Cabozantinib for 1st Line RCC
The CheckMate 9ER trial demonstrated that nivolumab plus cabozantinib significantly improved progression-free survival and overall survival compared to sunitinib in untreated advan
New Reference: Adjuvant Palbociclib for HR+ Breast Cancer
The five-year follow-up of the PALLAS trial did not show improved invasive disease-free survival with the addition of palbociclib to endocrine therapy in patients with early-stage
New Reference: Abemaciclib for Adjuvant Breast Cancer
Adjuvant abemaciclib plus endocrine therapy (ET) showed a significant but small improvement in overall survival compared to ET alone in HR-positive, HER2-negative, high-risk early
New Reference: Alectinib for ALK-Positive Advanced NSCLC
The ALEX study demonstrated that alectinib numerically prolongs overall survival compared to crizotinib in patients with untreated ALK-positive non-small cell lung cancer. Alectini
New Drug: Imlunestrant for ESR1-Mutated Advanced Breast Cancer
In patients with ESR1 mutations, imlunestrant significantly improved progression-free survival compared to standard therapy. Imlunestrant–abemaciclib further improved progression
New Indication: Amivantamab-Lazertinib for First Line Advanced EGFR-Mutated NSCLC
The MARIPOSA trial demonstrated that amivantamab-lazertinib significantly improved overall survival compared to osimertinib in EGFR-mutated advanced NSCLC in 1st line setting, with
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.